{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:53:13Z","timestamp":1767923593034,"version":"3.49.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"crossref","award":["24-75-10086"],"award-info":[{"award-number":["24-75-10086"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Government assignment for FRC Kazan Scientific Center of RAS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11010-025-05310-2","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:58:29Z","timestamp":1747828709000},"page":"5123-5139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Disease-modifying effect of donepezil on APP\/PS1 mice at different stages of Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"480","author":[{"given":"Irina","family":"Zueva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grigory","family":"Belyaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Petrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"5310_CR1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.24976\/Discov.Med.202335178.71","volume":"35","author":"C Zhang","year":"2023","unstructured":"Zhang C (2023) Etiology of Alzheimer\u2019s disease. Discov Med 35:757. https:\/\/doi.org\/10.24976\/Discov.Med.202335178.71","journal-title":"Discov Med"},{"key":"5310_CR2","doi-asserted-by":"publisher","unstructured":"(2024) 2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 20:3708\u20133821. https:\/\/doi.org\/10.1002\/alz.13809","DOI":"10.1002\/alz.13809"},{"key":"5310_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12385","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F (2023) Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimer & Dement Transl Res Clin Interv 9:e12385. https:\/\/doi.org\/10.1002\/trc2.12385","journal-title":"Alzheimer & Dement Transl Res Clin Interv"},{"key":"5310_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115522","volume":"211","author":"AR Monteiro","year":"2023","unstructured":"Monteiro AR, Barbosa DJ, Remi\u00e3o F, Silva R (2023) Alzheimer\u2019s disease: insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol 211:115522. https:\/\/doi.org\/10.1016\/j.bcp.2023.115522","journal-title":"Biochem Pharmacol"},{"key":"5310_CR5","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(23)00274-0","volume":"22","author":"CRS Belder","year":"2023","unstructured":"Belder CRS, Schott JM, Fox NC (2023) Preparing for disease-modifying therapies in Alzheimer\u2019s disease. Lancet Neurol 22:782\u2013783. https:\/\/doi.org\/10.1016\/S1474-4422(23)00274-0","journal-title":"Lancet Neurol"},{"key":"5310_CR6","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC et al (2023) Lecanemab: appropriate use recommendations. J Prev Alzheimer Dis. https:\/\/doi.org\/10.14283\/jpad.2023.30","journal-title":"J Prev Alzheimer Dis"},{"key":"5310_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S0306-4522(98)00397-2","volume":"89","author":"R Stancampiano","year":"1999","unstructured":"Stancampiano R, Cocco S, Cugusi C, Sarais L, Fadda F (1999) Serotonin and acetylcholine release response in the rat hippocampus during a spatial memory task. Neuroscience 89:1135\u20131143. https:\/\/doi.org\/10.1016\/S0306-4522(98)00397-2","journal-title":"Neuroscience"},{"key":"5310_CR8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.bbr.2010.11.058","volume":"221","author":"R Schliebs","year":"2011","unstructured":"Schliebs R, Arendt T (2011) The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221:555\u2013563. https:\/\/doi.org\/10.1016\/j.bbr.2010.11.058","journal-title":"Behav Brain Res"},{"key":"5310_CR9","doi-asserted-by":"publisher","first-page":"1399121","DOI":"10.3389\/fphar.2024.1399121","volume":"15","author":"AY Kim","year":"2024","unstructured":"Kim AY, AlJerdi S, MacDonald R, Triggle CR (2024) Alzheimer\u2019s disease and its treatment\u2013yesterday, today, and tomorrow. Front Pharmacol 15:1399121. https:\/\/doi.org\/10.3389\/fphar.2024.1399121","journal-title":"Front Pharmacol"},{"key":"5310_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00023210-200115020-00001","volume":"15","author":"E Giacobini","year":"2001","unstructured":"Giacobini E (2001) Do cholinesterase inhibitors have disease-modifying effects in Alzheimer\u2019s disease? CNS Drugs 15:85\u201391. https:\/\/doi.org\/10.2165\/00023210-200115020-00001","journal-title":"CNS Drugs"},{"key":"5310_CR11","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1097\/01.wad.0000213805.66811.31","volume":"20","author":"E Mori","year":"2006","unstructured":"Mori E, Hashimoto M, Ranga Krishnan K, Murali Doraiswamy P (2006) What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors? Alzheimer Dis Assoc Disord 20:S19\u2013S26. https:\/\/doi.org\/10.1097\/01.wad.0000213805.66811.31","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"5310_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1021\/acschemneuro.5b00040","volume":"6","author":"LA Mohamed","year":"2015","unstructured":"Mohamed LA, Qosa H, Kaddoumi A (2015) Age-related decline in brain and hepatic clearance of amyloid-beta is rectified by the cholinesterase inhibitors donepezil and rivastigmine in rats. ACS Chem Neurosci 6:725\u2013736. https:\/\/doi.org\/10.1021\/acschemneuro.5b00040","journal-title":"ACS Chem Neurosci"},{"key":"5310_CR13","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.neuroscience.2015.01.058","volume":"290","author":"HB Guo","year":"2015","unstructured":"Guo HB, Cheng YF, Wu JG, Wang CM, Wang HT, Zhang C, Qiu ZK, Xu JP (2015) Donepezil improves learning and memory deficits in APP\/PS1 mice by inhibition of microglial activation. Neuroscience 290:530\u2013542. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.01.058","journal-title":"Neuroscience"},{"key":"5310_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neuropharm.2015.02.020","volume":"95","author":"CY Ye","year":"2015","unstructured":"Ye CY, Lei Y, Tang XC, Zhang HY (2015) Donepezil attenuates A\u03b2-associated mitochondrial dysfunction and reduces mitochondrial A\u03b2 accumulation in vivo and in vitro. Neuropharmacology 95:29\u201336. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.02.020","journal-title":"Neuropharmacology"},{"key":"5310_CR15","doi-asserted-by":"publisher","first-page":"11706","DOI":"10.1038\/s41598-017-09780-3","volume":"7","author":"E Cavedo","year":"2017","unstructured":"Cavedo E, Grothe MJ, Colliot O, Lista S, Chupin M, Dormont D, Houot M, Leh\u00e9ricy S, Teipel S, Dubois B et al (2017) Reduced basal forebrain atrophy progression in a randomized donepezil trial in prodromal Alzheimer\u2019s disease. Sci Rep 7:11706. https:\/\/doi.org\/10.1038\/s41598-017-09780-3","journal-title":"Sci Rep"},{"key":"5310_CR16","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jalz.2014.10.003","volume":"11","author":"B Dubois","year":"2015","unstructured":"Dubois B, Chupin M, Hampel H, Lista S, Cavedo E, Croisile B, Louis Tisserand G, Touchon J, Bonafe A, Ousset PJ et al (2015) Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer\u2019s disease. Alzheimers Dement 11:1041\u20131049. https:\/\/doi.org\/10.1016\/j.jalz.2014.10.003","journal-title":"Alzheimers Dement"},{"key":"5310_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1176\/appi.ajp.162.4.676","volume":"162","author":"M Hashimoto","year":"2005","unstructured":"Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E (2005) Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer\u2019s disease? Am J Psychiatry 162:676\u2013682. https:\/\/doi.org\/10.1176\/appi.ajp.162.4.676","journal-title":"Am J Psychiatry"},{"key":"5310_CR18","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1176\/appi.ajp.160.11.2003","volume":"160","author":"KRR Krishnan","year":"2003","unstructured":"Krishnan KRR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S (2003) Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer\u2019s disease. Am J Psychiatry 160:2003\u20132011. https:\/\/doi.org\/10.1176\/appi.ajp.160.11.2003","journal-title":"Am J Psychiatry"},{"key":"5310_CR19","doi-asserted-by":"publisher","first-page":"2318.e31","DOI":"10.1016\/j.neurobiolaging.2010.04.005","volume":"32","author":"N Schuff","year":"2011","unstructured":"Schuff N, Suhy J, Goldman R, Xu Y, Sun Y, Truran-Sacrey D, Murthy A (2011) An MRI substudy of a donepezil clinical trial in mild cognitive impairment. Neurobiol Aging 32:2318.e31-2318.e41. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.04.005","journal-title":"Neurobiol Aging"},{"key":"5310_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1159\/000091790","volume":"21","author":"B Winblad","year":"2006","unstructured":"Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm A-L, Haglund A, Zhang R, Schindler R (2006) 3-Year study of donepezil therapy in Alzheimer\u2019s disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 21:353\u2013363. https:\/\/doi.org\/10.1159\/000091790","journal-title":"Dement Geriatr Cogn Disord"},{"key":"5310_CR21","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1212\/01.wnl.0000344650.95823.03","volume":"72","author":"RS Doody","year":"2009","unstructured":"Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK (2009) Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 72:1555\u20131561. https:\/\/doi.org\/10.1212\/01.wnl.0000344650.95823.03","journal-title":"Neurology"},{"key":"5310_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1212\/01.WNL.0000134664.80320.92","volume":"63","author":"S Salloway","year":"2004","unstructured":"Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S (2004) Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 63:651\u2013657. https:\/\/doi.org\/10.1212\/01.WNL.0000134664.80320.92","journal-title":"Neurology"},{"key":"5310_CR23","doi-asserted-by":"publisher","first-page":"772","DOI":"10.2174\/1567205016666190228122956","volume":"16","author":"E Mezeiova","year":"2019","unstructured":"Mezeiova E, Chalupova K, Nepovimova E, Gorecki L, Prchal L, Malinak D, Kuca K, Soukup O, Korabecny J (2019) Donepezil derivatives targeting amyloid-\u03b2 cascade in Alzheimer\u2019s disease. Curr Alzheimer Res 16:772\u2013800. https:\/\/doi.org\/10.2174\/1567205016666190228122956","journal-title":"Curr Alzheimer Res"},{"key":"5310_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ejmech.2018.09.031","volume":"158","author":"Q Li","year":"2018","unstructured":"Li Q, He S, Chen Y, Feng F, Qu W, Sun H (2018) Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer\u2019s disease. Eur J Med Chem 158:463\u2013477. https:\/\/doi.org\/10.1016\/j.ejmech.2018.09.031","journal-title":"Eur J Med Chem"},{"key":"5310_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/cmdc.202000484","volume":"16","author":"R Perone","year":"2021","unstructured":"Perone R, Albertini C, Uliassi E, Di Pietri F, De Sena Murteira Pinheiro P, Petralla S, Rizzardi N, Fato R, Pulkrabkova L, Soukup O et al (2021) Turning donepezil into a multi-target-directed ligand through a merging strategy. ChemMedChem 16:187\u2013198. https:\/\/doi.org\/10.1002\/cmdc.202000484","journal-title":"ChemMedChem"},{"key":"5310_CR26","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.3390\/ijms25115969","volume":"25","author":"R Mihaylova","year":"2024","unstructured":"Mihaylova R, Angelova VT, Tchekalarova J, Atanasova D, Ivanova P, Simeonova R (2024) Tailored melatonin- and donepezil-based hybrids targeting pathognomonic changes in Alzheimer\u2019s disease: an in vitro and in vivo investigation. Int J Mol Sci 25:5969. https:\/\/doi.org\/10.3390\/ijms25115969","journal-title":"Int J Mol Sci"},{"key":"5310_CR27","doi-asserted-by":"publisher","first-page":"30781","DOI":"10.1039\/D1RA03718H","volume":"11","author":"RT Kareem","year":"2021","unstructured":"Kareem RT, Abedinifar F, Mahmood EA, Ebadi AG, Rajabi F, Vessally E (2021) The recent development of donepezil structure-based hybrids as potential multifunctional anti-Alzheimer\u2019s agents: highlights from 2010 to 2020. RSC Adv 11:30781\u201330797. https:\/\/doi.org\/10.1039\/D1RA03718H","journal-title":"RSC Adv"},{"key":"5310_CR28","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3233\/JAD-2011-110551","volume":"26","author":"E Yang","year":"2011","unstructured":"Yang E, Farnum M, Lobanov V, Schultz T, Raghavan N, Samtani MN, Novak G, Narayan V, DiBernardo A (2011) Quantifying the pathophysiological timeline of Alzheimer\u2019s disease. J Alzheimers Dis 26:745\u2013753. https:\/\/doi.org\/10.3233\/JAD-2011-110551","journal-title":"J Alzheimers Dis"},{"key":"5310_CR29","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/sj.bjp.0706927","volume":"149","author":"J Meunier","year":"2006","unstructured":"Meunier J, Ieni J, Maurice T (2006) The anti-amnesic and neuroprotective effects of donepezil against amyloid \u03b225-35 peptide-induced toxicity in mice involve an interaction with the \u03c31 receptor. Br J Pharmacol 149:998\u20131012. https:\/\/doi.org\/10.1038\/sj.bjp.0706927","journal-title":"Br J Pharmacol"},{"key":"5310_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neuropharm.2019.05.025","volume":"155","author":"I Zueva","year":"2019","unstructured":"Zueva I, Dias J, Lushchekina S, Semenov V, Mukhamedyarov M, Pashirova T, Babaev V, Nachon F, Petrova N, Nurullin L et al (2019) New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer\u2019s disease. Neuropharmacology 155:131\u2013141. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.05.025","journal-title":"Neuropharmacology"},{"key":"5310_CR31","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.neubiorev.2020.02.012","volume":"112","author":"F Kosel","year":"2020","unstructured":"Kosel F, Pelley JMS, Franklin TB (2020) Behavioural and psychological symptoms of dementia in mouse models of Alzheimer\u2019s disease-related pathology. Neurosci Biobehav Rev 112:634\u2013647. https:\/\/doi.org\/10.1016\/j.neubiorev.2020.02.012","journal-title":"Neurosci Biobehav Rev"},{"key":"5310_CR32","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0896-6273(00)80230-5","volume":"17","author":"DR Borchelt","year":"1996","unstructured":"Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada C-M, Kim G, Seekins S, Yager D et al (1996) Familial Alzheimer\u2019s disease-linked presenilin 1 variants elevate A\u03b21\u201342\/1\u201340 ratio in vitro and in vivo. Neuron 17:1005\u20131013. https:\/\/doi.org\/10.1016\/S0896-6273(00)80230-5","journal-title":"Neuron"},{"key":"5310_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2047-9158-1-18","volume":"1","author":"S Dong","year":"2012","unstructured":"Dong S, Duan Y, Hu Y, Zhao Z (2012) Advances in the pathogenesis of Alzheimer\u2019s disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener 1:18. https:\/\/doi.org\/10.1186\/2047-9158-1-18","journal-title":"Transl Neurodegener"},{"key":"5310_CR34","doi-asserted-by":"publisher","unstructured":"(2024) Alzheimer\u2019s disease puzzle: delving into pathogenesis hypotheses. Aging Dis. https:\/\/doi.org\/10.14336\/AD.2023.0608","DOI":"10.14336\/AD.2023.0608"},{"key":"5310_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000369101","volume":"24","author":"S Sadigh-Eteghad","year":"2015","unstructured":"Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J (2015) Amyloid-beta: a crucial factor in Alzheimer\u2019s disease. Med Princ Pract 24:1\u201310. https:\/\/doi.org\/10.1159\/000369101","journal-title":"Med Princ Pract"},{"key":"5310_CR36","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.15252\/embj.201797397","volume":"36","author":"H Sasaguri","year":"2017","unstructured":"Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B, Saido TC (2017) APP mouse models for Alzheimer\u2019s disease preclinical studies. EMBO J 36:2473\u20132487. https:\/\/doi.org\/10.15252\/embj.201797397","journal-title":"EMBO J"},{"key":"5310_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nprot.2006.2","volume":"1","author":"RMJ Deacon","year":"2006","unstructured":"Deacon RMJ, Rawlins JNP (2006) T-maze alternation in the rodent. Nat Protoc 1:7\u201312. https:\/\/doi.org\/10.1038\/nprot.2006.2","journal-title":"Nat Protoc"},{"key":"5310_CR38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/BF02284844","volume":"25","author":"ME Calhoun","year":"1996","unstructured":"Calhoun ME, Jucker M, Martin LJ, Thinakaran G, Price DL, Mouton PR (1996) Comparative evaluation of synaptophysin-based methods for quantification of synapses. J Neurocytol 25:821\u2013828. https:\/\/doi.org\/10.1007\/BF02284844","journal-title":"J Neurocytol"},{"key":"5310_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/molecules27061816","volume":"2022","author":"Z-R Chen","year":"1816","unstructured":"Chen Z-R, Huang J-B, Yang S-L, Hong F-F (1816) Role of cholinergic signaling in Alzheimer\u2019s disease. Molecules 2022:27. https:\/\/doi.org\/10.3390\/molecules27061816","journal-title":"Molecules"},{"key":"5310_CR40","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam M-M, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ et al (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain 141:1917\u20131933. https:\/\/doi.org\/10.1093\/brain\/awy132","journal-title":"Brain"},{"key":"5310_CR41","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/(SICI)1096-9861(19970224)378:4<454::AID-CNE2>3.0.CO;2-1","volume":"378","author":"U Arvidsson","year":"1997","unstructured":"Arvidsson U, Riedl M, Elde R, Meister B (1997) Vesicular Acetylcholine Transporter (VAChT) protein: a novel and unique marker for cholinergic neurons in the central and peripheral nervous systems. J Comp Neurol 378:454\u2013467. https:\/\/doi.org\/10.1002\/(SICI)1096-9861(19970224)378:4%3c454::AID-CNE2%3e3.0.CO;2-1","journal-title":"J Comp Neurol"},{"key":"5310_CR42","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1523\/JNEUROSCI.18-09-03213.1998","volume":"18","author":"A Alvarez","year":"1998","unstructured":"Alvarez A, Alarc\u00f3n R, Opazo C, Campos EO, Mu\u00f1oz FJ, Calder\u00f3n FH, Dajas F, Gentry MK, Doctor BP, De Mello FG et al (1998) Stable complexes involving acetylcholinesterase and amyloid-\u03b2 peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer\u2019s fibrils. J Neurosci 18:3213\u20133223. https:\/\/doi.org\/10.1523\/JNEUROSCI.18-09-03213.1998","journal-title":"J Neurosci"},{"key":"5310_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.110065","volume":"364","author":"SP Maxwell","year":"2022","unstructured":"Maxwell SP, Cash MK, Darvesh S (2022) Neuropathology and cholinesterase expression in the brains of octogenarians and older. Chem Biol Interact 364:110065. https:\/\/doi.org\/10.1016\/j.cbi.2022.110065","journal-title":"Chem Biol Interact"},{"key":"5310_CR44","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1177\/34.11.2430009","volume":"34","author":"H Tago","year":"1986","unstructured":"Tago H, Kimura H, Maeda T (1986) Visualization of detailed acetylcholinesterase fiber and neuron staining in rat brain by a sensitive histochemical procedure. J Histochem Cytochem 34:1431\u20131438. https:\/\/doi.org\/10.1177\/34.11.2430009","journal-title":"J Histochem Cytochem"},{"key":"5310_CR45","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.2174\/1381612825666191008103141","volume":"25","author":"MdT Kabir","year":"2019","unstructured":"Kabir MdT, Uddin MdS, Begum MstM, Thangapandiyan S, Rahman MdS, Aleya L, Mathew B, Ahmed M, Barreto GE, Ashraf GMd (2019) Cholinesterase inhibitors for Alzheimer\u2019s disease: multitargeting strategy based on anti-Alzheimer\u2019s drugs repositioning. Curr Pharm Des 25:3519\u20133535. https:\/\/doi.org\/10.2174\/1381612825666191008103141","journal-title":"Curr Pharm Des"},{"key":"5310_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.nurt.2008.10.030","volume":"6","author":"O Weinreb","year":"2009","unstructured":"Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T, Youdim MBH (2009) Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer\u2019s disease drugs. Neurotherapeutics 6:163\u2013174. https:\/\/doi.org\/10.1016\/j.nurt.2008.10.030","journal-title":"Neurotherapeutics"},{"key":"5310_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2016.00205","author":"M Unzeta","year":"2016","unstructured":"Unzeta M, Esteban G, Bolea I, Fogel WA, Ramsay RR, Youdim MBH, Tipton KF, Marco-Contelles J (2016) Multi-target directed donepezil-like ligands for Alzheimer\u2019s disease. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2016.00205","journal-title":"Front Neurosci"},{"key":"5310_CR48","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.3390\/ijms25052805","volume":"25","author":"MS P\u00e1dua","year":"2024","unstructured":"P\u00e1dua MS, Guil-Guerrero JL, Prates JAM, Lopes PA (2024) Insights on the use of transgenic mice models in Alzheimer\u2019s disease research. Int J Mol Sci 25:2805. https:\/\/doi.org\/10.3390\/ijms25052805","journal-title":"Int J Mol Sci"},{"key":"5310_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd.2017.244","volume":"17","author":"P Morgan","year":"2018","unstructured":"Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, Fidock M, Hamr\u00e9n B, Johnson A, March RE et al (2018) Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov 17:167\u2013181. https:\/\/doi.org\/10.1038\/nrd.2017.244","journal-title":"Nat Rev Drug Discov"},{"key":"5310_CR50","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1126\/science.aau0437","volume":"362","author":"TE Golde","year":"2018","unstructured":"Golde TE, DeKosky ST, Galasko D (2018) Alzheimer\u2019s disease: the right drug, the right time. Science 362:1250\u20131251. https:\/\/doi.org\/10.1126\/science.aau0437","journal-title":"Science"},{"key":"5310_CR51","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","volume":"11","author":"J Cummings","year":"2019","unstructured":"Cummings J, Feldman HH, Scheltens P (2019) The, \u201cRights\u201d of precision drug development for Alzheimer\u2019s disease. Alzheimers Res Therapy 11:76. https:\/\/doi.org\/10.1186\/s13195-019-0529-5","journal-title":"Alzheimers Res Therapy"},{"key":"5310_CR52","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.tins.2022.11.006","volume":"46","author":"KM Igarashi","year":"2023","unstructured":"Igarashi KM (2023) Entorhinal cortex dysfunction in Alzheimer\u2019s disease. Trends Neurosci 46:124\u2013136. https:\/\/doi.org\/10.1016\/j.tins.2022.11.006","journal-title":"Trends Neurosci"},{"key":"5310_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","volume":"14","author":"TH Ferreira-Vieira","year":"2016","unstructured":"Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM (2016) Alzheimer\u2019s disease: targeting the cholinergic system. Curr Neuropharmacol 14:101\u2013115. https:\/\/doi.org\/10.2174\/1570159X13666150716165726","journal-title":"Curr Neuropharmacol"},{"key":"5310_CR54","doi-asserted-by":"publisher","first-page":"518","DOI":"10.2174\/1567205016666190517121140","volume":"16","author":"L Guzman-Martinez","year":"2019","unstructured":"Guzman-Martinez L, Maccioni RB, Far\u00edas GA, Fuentes P, Navarrete LP (2019) Biomarkers for Alzheimer\u2019s disease. Curr Alzheimer Res 16:518\u2013528. https:\/\/doi.org\/10.2174\/1567205016666190517121140","journal-title":"Curr Alzheimer Res"},{"key":"5310_CR55","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1038\/s41380-022-01565-z","volume":"27","author":"L Peng","year":"2022","unstructured":"Peng L, Bestard-Lorigados I, Song W (2022) The synapse as a treatment avenue for Alzheimer\u2019s disease. Mol Psychiatry 27:2940\u20132949. https:\/\/doi.org\/10.1038\/s41380-022-01565-z","journal-title":"Mol Psychiatry"},{"key":"5310_CR56","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2174\/1567205016666190321163438","volume":"16","author":"L Pinheiro","year":"2019","unstructured":"Pinheiro L, Faustino C (2019) Therapeutic strategies targeting amyloid-\u03b2 in Alzheimer\u2019s disease. Curr Alzheimer Res 16:418\u2013452. https:\/\/doi.org\/10.2174\/1567205016666190321163438","journal-title":"Curr Alzheimer Res"},{"key":"5310_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13195-022-00994-w","volume":"14","author":"W Liu","year":"2022","unstructured":"Liu W, Li J, Yang M, Ke X, Dai Y, Lin H, Wang S, Chen L, Tao J (2022) Chemical genetic activation of the cholinergic basal forebrain hippocampal circuit rescues memory loss in Alzheimer\u2019s disease. Alzheimers Res Therapy 14:53. https:\/\/doi.org\/10.1186\/s13195-022-00994-w","journal-title":"Alzheimers Res Therapy"},{"key":"5310_CR58","doi-asserted-by":"publisher","first-page":"e02444","DOI":"10.7554\/eLife.02444","volume":"3","author":"H Wu","year":"2014","unstructured":"Wu H, Williams J, Nathans J (2014) Complete morphologies of basal forebrain cholinergic neurons in the mouse. eLife 3:e02444. https:\/\/doi.org\/10.7554\/eLife.02444","journal-title":"eLife"},{"key":"5310_CR59","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/(SICI)1096-9861(19990906)411:4<693::AID-CNE13>3.0.CO;2-D","volume":"411","author":"ML Gilmor","year":"1999","unstructured":"Gilmor ML, Erickson JD, Varoqui H, Hersh LB, Bennett DA, Cochran EJ, Mufson EJ, Levey AI (1999) Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer\u2019s disease. J Comp Neurol 411:693\u2013704","journal-title":"J Comp Neurol"},{"key":"5310_CR60","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1111\/bph.14030","volume":"174","author":"SH Kim","year":"2017","unstructured":"Kim SH, Kandiah N, Hsu J, Suthisisang C, Udommongkol C, Dash A (2017) Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer\u2019s disease. Br J Pharmacol 174:4224\u20134232. https:\/\/doi.org\/10.1111\/bph.14030","journal-title":"Br J Pharmacol"},{"key":"5310_CR61","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0014-5793(99)00468-8","volume":"450","author":"FJ Mu\u00f1oz","year":"1999","unstructured":"Mu\u00f1oz FJ, Inestrosa NC (1999) Neurotoxicity of acetylcholinesterase amyloid \u0392-peptide aggregates is dependent on the type of A\u03b2 peptide and the AChE concentration present in the complexes. FEBS Lett 450:205\u2013209. https:\/\/doi.org\/10.1016\/S0014-5793(99)00468-8","journal-title":"FEBS Lett"},{"key":"5310_CR62","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0002-9440(10)63774-1","volume":"164","author":"AE Reyes","year":"2004","unstructured":"Reyes AE, Chac\u00f3n MA, Dinamarca MC, Cerpa W, Morgan C, Inestrosa NC (2004) Acetylcholinesterase-A\u03b2 complexes are more toxic than A\u03b2 fibrils in rat hippocampus. Am J Pathol 164:2163\u20132174. https:\/\/doi.org\/10.1016\/S0002-9440(10)63774-1","journal-title":"Am J Pathol"},{"key":"5310_CR63","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/0006-8993(87)90808-0","volume":"406","author":"H Tago","year":"1987","unstructured":"Tago H, McGeer PL, McGeer EG (1987) Acetylcholinesterase fibers and the development of senile plaques. Brain Res 406:363\u2013369. https:\/\/doi.org\/10.1016\/0006-8993(87)90808-0","journal-title":"Brain Res"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05310-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-025-05310-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05310-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:47:39Z","timestamp":1758970059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-025-05310-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["5310"],"URL":"https:\/\/doi.org\/10.1007\/s11010-025-05310-2","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial and non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Animal Care and Use Committee of FRC Kazan Scientific Center of RAS (Protocol No. 9 from 4 December 2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}